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Allogeneic hematopoietic cell transplantation (allo-HCT) is the
treatment of choice for younger patients with intermediate or
high-risk AML in ﬁrst CR, as well as for younger patients with AML
beyond ﬁrst CR.1 AML cure following allo-HCT depends in a large
part on graft-versus-AML effects mediated by donor immune cells
contained in the graft. Although graft-versus-AML effects have
been associated with occurrence of GvHD,2,3 the observation of
lower risks of relapse in allo-HCT patients not experiencing GvHD
in comparison with patients transplanted with grafts from
identical twins, demonstrated that graft-versus-AML effects can
occur without clinical GvHD.2
In an attempt to extend the use of allo-HCT to older patients
and those with medical comorbid conditions, several groups of
investigators have carried out allo-HCT after reduced intensity
(RIC) or truly nonmyeloablative conditioning regimens.4,5
These regimens rely on graft-versus-AML effects rather than
on chemo/radiotherapy for tumor eradication.3,6 Remarkably,
a recent study by the HOVON/SAKK group demonstrated that
RIC/nonmyeloablative allo-HCT improved overall survival (OS) in
older (60 years of age or older) patients with intermediate or
high-risk AML in comparison with those not transplanted.7
Nevertheless, disease relapse remained the ﬁrst cause of death
even in RIC/nonmyeloablative allo-HCT recipients.7
The outcome of AML patients who relapse after allo-HCT
remains poor.8 Donor lymphocyte infusion (DLI) can result in
prolonged CR but only in a minority of patients with low-disease
burden.9 Similarly, an association of DLI and azacitidine induces
only a few persistent CR,10 whereas a second allo-HCT (in a group
of highly selected patients) results in a 2-year OS rate of
~ 20%.11,12
Given the poor prognosis of patients who experience relapse
after allo-HCT, several groups of investigators have assessed
various post-transplant approaches aimed at preventing disease
relapse in high-risk AML patients (Table 1). These approaches
include decreasing the level of post-grafting immunosuppression,13
preemptive (i.e., administered in patients with post-transplant
evidence of minimal residual disease or low / decreasing donor
chimerism levels) or prophylactic administration of disease-
speciﬁc medications such as demethylating agents14 or FLT3
inhibitors,15 or preemptive16,17 or prophylactic DLI.18,19
In this issue of Bone Marrow Transplantation, Jedlickova et al.20
report the results of a retrospective analysis assessing the safety
and efﬁcacy of prophylactic DLI in a cohort of 46 high-risk AML
patients given grafts following a sequential treatment consisting
of chemotherapy (FLAMSA) followed by RIC allo-HCT. Post-grafting
immunosuppression included cyclosporine tapered from day +60
to +90 and mycophenolate mofetil discontinued by day +45.
Criteria for prophylactic DLI included remaining in CR for at least
120 days after transplantation, being off immunosuppression
for at least 30 days, absence of GvHD and no antecedent of grade
III–IV acute GvHD. The initial dose of DLI was relatively low: 1 × 106
T cells/kg recipient in sibling (MSD) transplant recipients and
0.5 × 106 T cells/kg in unrelated graft (UD) recipients. In the
absence of GvHD, DLI were repeated up to three times using
escalating T-cell doses (ﬁve- to 10-fold increase/DLI) at 4–6 weeks
intervals. Speciﬁcally, 7 patients were given one, 15 patients two
Table 1. Post-transplant approaches aimed at preventing relapse in high-risk AML patients
Approach Mechanisms of action Potential limitations
Low exposure to CNI the ﬁrst weeks after
transplantation13
- Increases GV-AML effects - Increases risk of GvHD?
Early post-grafting immunosuppression
discontinuation22
- Increases GV-AML effects - Increases risk of GvHD?
Demethylating agents14,23 - Direct antileukemic activity - Hematological toxicity
- Induce expression of tumor antigens
by AML blasts
- Induction of regulatory T cells that might affect
GVT effects.
FLT3 inhibitors15 - Direct antileukemic activity - Hematological toxicity
- Only efﬁcient in FLT3-mutated AML?
Preemptive DLI16,17 - Increases GV-AML effects - Increases risk of GvHD
- Request frequent assessment of MRD or of
lineage-speciﬁc chimerism
Prophylactic DLI18 - Increases GV-AML effects - Increases risk of GvHD
Abbreviations: CNI=calcineurin inhibitor; DLI=donor lymphocyte infusion; GV-AML=graft-versus-AML effects.
GIGA-I3, Laboratory of Hematology and Department of Hematology, Centre Hospitalier Universitaire (CHU), University of Liège, Liège, Belgium. Correspondence: Dr F Baron,
Department of Hematology, Centre Hospitalier Universitaire, University of Liège, Sart-Tilman, Liège B4000, Belgium.
E-mail: f.baron@ulg.ac.be
Received 8 December 2015; accepted 10 December 2015; published online 14 March 2016
Bone Marrow Transplantation (2016) 51, 640–642
© 2016 Macmillan Publishers Limited All rights reserved 0268-3369/16
www.nature.com/bmt
and 24 patients three DLI. The rationale for giving DLI in escalating
doses was based on prior observations by Dazzi et al.21
who demonstrated that, in comparison with single-dose DLI,
escalating-dose DLI were as efﬁcient but signiﬁcantly less often
complicated by GvHD. The median time from transplantation to
ﬁrst DLI was 160 days. Transplantation outcomes of patients given
prophylactic DLI were compared with those of a group of 34
control patients fulﬁlling the criteria for high-risk AML and
prophylactic DLI but who were transplanted during the same
time period in centers not administering prophylactic DLI. Seventy
percent of DLI patients and 60% of control patients were either
refractory or in untreated relapse.
Following DLI, only 4 patients (9%) developed grade II–IV acute
GvHD and 5 (11%) extensive chronic GvHD. Seven-year OS was
67% in DLI versus 31% in control patients, respectively, (Po0.001).
In a pseudo landmark analysis, starting the day of ﬁrst DLI in DLI
patients and on day +160 in control patients, 6-year leukemia-free
survival was 68% in DLI patients versus 38% in control patients
(P= 0.01). This was owing to a lower risk of relapse in DLI patients
(22 versus 53%, P= 0.004).
There are some limitations in the study by Jedlickova et al.20
including the diversity of disease status at transplantation, the
retrospective design of the study and some differences between
DLI and control patients (including the type of conditioning
regimen and GvHD prophylaxis). However, the study is informative
for several aspects. First, the study shows that prophylactic DLI
given in escalating doses starting after day 120 following
transplantation are well tolerated with o15% of patients
developing grade II–IV or extensive chronic GvHD. This might be
due to the fact that DLIs were given in escalating doses21 and
were started relatively late after transplantation (and thus at least
30 days after cyclosporine discontinuation). Second, the relapse
incidence was signiﬁcantly lower in DLI than in control patients
suggesting that prophylactic DLI prevented relapse. Third, the
lower risk of relapse in DLI patients translated into improved
leukemia-free survival.
Another prospective study of prophylactic DLI in patients with
high-risk acute leukemia has been reported by Liga et al.19 2 years
ago. In that study, patients were given allo-HCT following a
low-dose (10–20 mg total dose) alemtuzumab-containing con-
ditioning regimen. The starting dose of DLI was 0.75 × 106 cells/kg
(escalated up to 1.5 × 106 CD3+ cells/kg) in MSD recipients and
0.5 × 106 cells/kg (escalated up to 1 × 106 CD3+ cells/kg) in UD
recipients. DLI were scheduled to start 2–4 weeks after
cyclosporine discontinuation. Main criteria for DLI included no
evidence of disease relapse, no history of 4grade 1 acute GvHD,
no active GvHD at the time of planned DLI and off immunother-
apy. Fifteen patients (out of 56 consecutive patients registered)
received prophylactic DLI a median of 162 days after allo-HCT. As
observed in the Jedlickova et al.20 study, the relapse incidence was
very low after prophylactic DLI (none of the 15 patients). However,
in contrast to what was observed by Jedlickova et al.,20 4 of 15
patients died of steroid-refractory GvHD. Reasons for this apparent
discrepancy are unclear. One possible explanation might be that
the low doses of alemtuzumab given in the Liga et al.19 study
impaired the recovery of regulatory T cells. Another possible
explanation might be that DLI were given as soon as 2 weeks after
cyclosporine discontinuation in the Liga et al.19 study, versus at
least 30 days, in the study by Jedlickova et al.20
Although the data reported by Jedlickova et al.20 are impressive,
prospective randomized studies are needed to conﬁrm the beneﬁt
of prophylactic DLIs in patients transplanted for high-risk AML,
and also to compare strategies of prophylactic versus
preemptive DLI.
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